EVALUATION OF DRUG-RELATED PROBLEMS IN THE CATEGORY OF DRUG INTERACTIONS IN TUBERCULOSIS TREATMENT AMONG OUTPATIENTS AT TERATAK PUBLIC HEALTH CENTER
DOI:
https://doi.org/10.37824/7dbfj125Keywords:
Tuberculosis, Drug-Related Problems, Drug Interactions, OAT, Teratak Public Health Center.Abstract
Tuberculosis (TB) remains a major global health problem, including in Indonesia, due to its high incidence and mortality. The concomitant use of anti tuberculosis drugs (ATDs) with medications for comorbidities may cause Drug Related Problems (DRPs), particularly drug interactions, which can affect treatment effectiveness and safety. This study aimed to evaluate drug interaction related DRPs among TB outpatients at Teratak Public Health Center. A non experimental descriptive quantitative study with a retrospective approach was conducted using medical records of TB patients from January to December 2024. Samples were selected by total sampling, and drug interactions were identified using DrugBank and Drugs.com. Most patients were male (69.2%), with the highest proportion in the early elderly, late elderly, and geriatric groups (19.2% each). Eight potential drug interactions between ATDs and non ATDs were identified. Most interactions were classified as minor (50.0%), followed by moderate (40.0%) and major (10.0%). The major interaction involved rifampicin and amlodipine, which may reduce antihypertensive effectiveness. Overall, drug interactions were predominantly low severity. Regular monitoring and evaluation by healthcare professionals are recommended, especially for patients with comorbidities, to maintain therapeutic effectiveness and minimize adverse drug reactions.
Keywords: Tuberculosis, Drug-Related Problems, Teratak Public Health Center
References
[1] Amal, A. (2021). Drug-related problems in infectious disease therapy. Jakarta: EGC.
(2) Kementerian Kesehatan Republik Indonesia. (2022). Indonesia TB situation report. Jakarta: Kemenkes RI.
(3) Syamsudin, S. (2011). Drug interactions and their impact on therapy. Yogyakarta: Gadjah Mada University Press.
(4) Tatro, D. (2018). Drug interaction facts. St. Louis, MO: Wolters Kluwer Health.
(5) World Health Organization. (2022). Global tuberculosis report. Geneva: World Health Organization.
(6) Khutsiyah, L. (2018). Potential drug interactions in outpatient pulmonary tuberculosis patients at Dr. Soegiri Lamongan Hospital in 2017
[Undergraduate thesis, UIN Maulana Malik Ibrahim Malang].
(7) Khotimah, K., & Sutrisna, E. M. (2023). Identification of drug-related problems (DRPs) in intensive phase tuberculosis treatment among geriatric patients at Surakarta General Hospital. Medical Sains: Jurnal Ilmiah Kefarmasian, 8(3), 945–953.
(8) Lestari, D. F. (2021). Analysis of potential drug–drug interactions in drug-resistant tuberculosis patients at Tangerang Selatan General Hospital during 2019–2021. Jurnal Ilmu Kefarmasian Indonesia, 19(2), 155–163.
https://doi.org/10.22435/jifi.v19i2.537 2
(9) Manson, G. C., & Zumla, A. I. (Eds.). (2008). Manson’s tropical diseases (22nd ed.). Saunders Elsevier.
(10) Utami, S., Athiyah, U., & Nita, Y. (2022). Signal detection of adverse drug reaction
to first-line anti-tuberculosis drugs using the Indonesian pharmacovigilance database. Pharmacy Education, 22(2), 270–274.
https://doi.org/10.46542/pe.2022.222. 270274
(11) Veryanti, P. R., Ni, P. K. D., & Dian, P. (2019). Potential drug interactions of anti-tuberculosis drugs in the inpatient installation of X General Hospital Jakarta during 2016. Sainstech Farma (SFJ): Jurnal Ilmu Kefarmasian, 12(1), 23–31.
(12) Yasuda, S., Horai, Y., Tomono, Y., Nakai, D., & Yamato, C. (2002). The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. British Journal of Clinical Pharmacology, 53(5), 519–525.
